This article is more than 5 years old. Information may no longer be current.

Clarient adds bioMérieux’s diagnostic test for BRAF mutations in metastatic melanoma

Clarient Diagnostic Services announced it has added bioMérieux’s molecular diagnostic test to its technologies to detect BRAF mutations in patients with metastatic melanoma.

The THxID BRAF kit is a novel assay that received premarket approval from the FDA in May to aid in selecting patients with melanoma whose tumors carry the BRAF V600E mutation for treatment with dabrafenib (Tafinlar, GlaxoSmithKline) and whose tumors carry the BRAF V600E or V600K mutation for therapy with trametinib (Mekinist, GlaxoSmithKline).

“This unique test will bring clarity and precision to physicians to assist them in making better treatment decisions for their patients,” Cynthia Collins, Clarient general manager, said in a press release.

“We are very pleased to partner with Clarient,” Mark Miller, MD, chief medical officer of bioMérieux, said in the release. “Together, we aim to provide clinicians with key information to help them choose an appropriate treatment for their melanoma patients.”